CRA provided expert reports and testimony in several cases involving improper diversion of diabetes test strips. CRA’s damages analyses quantified the difference in profits earned on legitimate sales of test strips in the US retail market as compared to profits earned on the diverted test strips (for example, those sold in international markets or those intended for other patient groups in the US).
Trade Secret Litigation Watch: February 2026
In this second installment of the Trade Secret Litigation Watch, CRA’s Intellectual Property team examines emerging trends and case outcomes with an emphasis...